Catalyst Pharmaceuticals (CPRX) EBT Margin (2018 - 2026)
Catalyst Pharmaceuticals (CPRX) posted EBT Margin of 56.38% for Q1 2026, up 19.67% on a QoQ basis from 47.11% in Q4 2025, and up 598.0% year-over-year from 8.08% in Q1 2025.
Catalyst Pharmaceuticals (CPRX) EBT Margin (2018 - 2026) Analysis & Trends
Catalyst Pharmaceuticals' EBT Margin history runs 9 years deep, the most recent figure standing at 56.38% for Q1 2026.
- Quarterly EBT Margin rose 598.0% year-over-year to 56.38% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 49.66% (up 132.0% YoY) and the FY2025 annual result came in at 48.14%, up 416.0% from the prior year.
- EBT Margin was 56.38% for Q1 2026 at Catalyst Pharmaceuticals, up from 47.11% in the prior quarter.
- Across five years, EBT Margin topped out at 56.38% in Q1 2026 and bottomed at 37.03% in Q3 2023.
- A 5-year average of 41.88% and a median of 47.11% in 2025 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin plunged 8246 bps — and 2024, when it soared 8148 bps.
- Catalyst Pharmaceuticals' EBT Margin stood at 54.33% in 2022, then slipped by 22 bps to 42.24% in 2023, then increased by 24 bps to 52.31% in 2024, then retreated by 10 bps to 47.11% in 2025, then advanced by 20 bps to 56.38% in 2026.
- Business Quant data shows CPRX's EBT Margin at 56.38% in Q1 2026, 47.11% in Q4 2025, and 47.87% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 56.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.38% |
| Dec 31, 2025 | 47.11% |
| Sep 30, 2025 | 47.87% |
| Jun 30, 2025 | 47.28% |
| Mar 31, 2025 | 50.41% |
| Dec 31, 2024 | 52.31% |
| Sep 30, 2024 | 44.45% |
| Jun 30, 2024 | 45.46% |
| Mar 31, 2024 | 29.53% |
| Dec 31, 2023 | 42.24% |
| Sep 30, 2023 | -37.03% |
| Jun 30, 2023 | 48.72% |
| Mar 31, 2023 | 43.71% |
| Dec 31, 2022 | 54.33% |
| Sep 30, 2022 | 45.43% |
| Jun 30, 2022 | 53.18% |
| Mar 31, 2022 | 40.52% |
| Dec 31, 2021 | 33.45% |
| Sep 30, 2021 | 39.14% |
| Jun 30, 2021 | 43.72% |